WASHINGTON — The White House isn’t worried about Congress underfunding the new biomedical research agency President Biden has pitched as a way to “end cancer as we know it.”
Not yet, anyway, according to Tara Schwetz, the biophysicist who the administration has tapped to get the new agency off the ground. In an interview, Schwetz said the $3 billion that House Democrats plan to spend on the new agency, to be known as ARPA-H, is “a substantial amount,” even though it’s less than half of the $6.5 billion the Biden administration had requested.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
